Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

An evaluation of a leadership development coaching and mentoring programme.

Le Comte L, McClelland B.

Leadersh Health Serv (Bradf Engl). 2017 Jul 3;30(3):309-329. doi: 10.1108/LHS-07-2016-0030.

PMID:
28693394
2.

Using Decision Analysis to Understand the Indications for Unilateral Hand Transplantation.

McClelland B, Novak CB, Hanna S, McCabe SJ.

Hand (N Y). 2016 Dec;11(4):450-455. doi: 10.1177/1558944715628008. Epub 2016 Mar 8.

PMID:
28149213
3.

Evaluating the delivery, impact, costs and benefits of an active lives programme for older people living in the community.

Gandy R, Bell A, McClelland B, Roe B.

Prim Health Care Res Dev. 2017 Mar;18(2):122-134. doi: 10.1017/S146342361600027X. Epub 2016 Aug 19.

PMID:
27539292
4.

Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.

Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, Peeters A, Farrall AJ, Adami A, Potter G, Cohen G, Sandercock PA, Lindley RI, Wardlaw JM; IST-3 Collaborative Group.

Neurology. 2016 Jan 12;86(2):118-25. doi: 10.1212/WNL.0000000000002236. Epub 2015 Dec 9.

5.

End of life care: The experiences of advance care planning amongst family caregivers of people with advanced dementia - A qualitative study.

Ashton SE, Roe B, Jack B, McClelland B.

Dementia (London). 2016 Sep;15(5):958-75. doi: 10.1177/1471301214548521. Epub 2014 Sep 3.

PMID:
25187482
6.

Synthetic versus plaster of Paris casts in the treatment of fractures of the forearm in children: a randomised trial of clinical outcomes and patient satisfaction.

Inglis M, McClelland B, Sutherland LM, Cundy PJ.

Bone Joint J. 2013 Sep;95-B(9):1285-9. doi: 10.1302/0301-620X.95B9.30666.

PMID:
23997147
7.

Thrombocytopenia and platelet transfusion in UK critical care: a multicenter observational study.

Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll DL; Intensive Care Study of Coagulopathy Investigators.

Transfusion. 2013 May;53(5):1050-8. doi: 10.1111/j.1537-2995.2012.03866.x. Epub 2012 Aug 28.

PMID:
22928908
8.

Current issues with standards in the measurement and documentation of human skeletal anatomy.

Magee J, McClelland B, Winder J.

J Anat. 2012 Sep;221(3):240-51. doi: 10.1111/j.1469-7580.2012.01535.x. Epub 2012 Jul 2.

9.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A.

Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

10.

EHRs: watching and waiting.

McClelland B.

Fam Pract Manag. 2011 Nov-Dec;18(6):8. No abstract available.

11.

Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.

Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, Whiteley W, Perry D, Soosay V, Buchanan D, Venables G, Czlonkowska A, Kobayashi A, Berge E, Slot KB, Murray V, Peeters A, Hankey GJ, Matz K, Brainin M, Ricci S, Cantisani TA, Gubitz G, Phillips SJ, Antonio A, Correia M, Lyrer P, Kane I, Lundstrom E; IST-3 collaborative group.

Trials. 2011 Nov 30;12:252. doi: 10.1186/1745-6215-12-252.

12.

Treatment of neonatal sepsis with intravenous immune globulin.

INIS Collaborative Group, Brocklehurst P, Farrell B, King A, Juszczak E, Darlow B, Haque K, Salt A, Stenson B, Tarnow-Mordi W.

N Engl J Med. 2011 Sep 29;365(13):1201-11. doi: 10.1056/NEJMoa1100441.

13.

A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time.

Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll D; Intensive Care Study of Coagulopathy (ISOC) investigators.

Crit Care. 2011;15(2):R108. doi: 10.1186/cc10129. Epub 2011 Apr 5.

14.

Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.

Carless PA, Henry DA, Carson JL, Hebert PP, McClelland B, Ker K.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD002042. doi: 10.1002/14651858.CD002042.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD002042.

PMID:
20927728
15.

A review of methods used in comprehensive, descriptive studies that relate red blood cell transfusion to clinical data.

Biggin K, Warner P, Prescott R, McClelland B.

Transfusion. 2010 Mar;50(3):711-8. doi: 10.1111/j.1537-2995.2009.02459.x. Epub 2009 Nov 19. Review.

PMID:
19929863
16.

Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, Laupacis A, Fergusson D.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD001886. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD001886.

PMID:
17943760
17.

Clinical quality improvement information for transfusion practice.

McClelland B.

Transfusion. 2007 Aug;47(2 Suppl):137S-141S; discussion 155S-156S. Review. No abstract available.

PMID:
17651337
18.

Why do we believe in red cell transfusion?

McClelland B.

Dev Biol (Basel). 2007;127:3-8. Review. No abstract available.

PMID:
17486877
19.

Appropriateness and safety of blood transfusion.

McClelland B, Contreras M.

BMJ. 2005 Jan 15;330(7483):104-5. No abstract available.

20.

Desmopressin for minimising perioperative allogeneic blood transfusion.

Carless PA, Henry DA, Moxey AJ, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D.

Cochrane Database Syst Rev. 2004;(1):CD001884. Review. Update in: Cochrane Database Syst Rev. 2017 Jul 10;7:CD001884.

Supplemental Content

Loading ...
Support Center